Literature DB >> 30919304

Authors' Reply to Gough: "Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes".

Sudesna Chatterjee1,2, Kamlesh Khunti3, Melanie Davies3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30919304     DOI： 10.1007/s40265-019-01093-1

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  6 in total

Review 1.  Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes.

Authors:  Sudesna Chatterjee; Kamlesh Khunti; Melanie J Davies
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

2.  Comment on: "Achieving Glycaemic Control with Concentrated Insulin in Patients with Type 2 Diabetes".

Authors:  Stephen Gough
Journal:  Drugs       Date:  2019-04       Impact factor: 9.546

3.  Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

Authors:  Ib Jonassen; Svend Havelund; Thomas Hoeg-Jensen; Dorte Bjerre Steensgaard; Per-Olof Wahlund; Ulla Ribel
Journal:  Pharm Res       Date:  2012-04-07       Impact factor: 4.200

Review 4.  Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes.

Authors:  Tim Heise; Chantal Mathieu
Journal:  Diabetes Obes Metab       Date:  2016-09-26       Impact factor: 6.577

5.  Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 Diabetes.

Authors:  Matthew C Riddle; Geremia B Bolli; Philip D Home; Richard M Bergenstal; Monika Ziemen; Isabel Muehlen-Bartmer; Marek Wardecki; Laetitia Vinet; Nathalie Jeandidier; Hannele Yki-Järvinen
Journal:  Diabetes Technol Ther       Date:  2016-02-03       Impact factor: 6.118

6.  Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial.

Authors:  Takashi Kadowaki; Hideaki Jinnouchi; Kohei Kaku; Malene L Hersløv; Jacob Hyllested-Winge; Shuji Nakamura
Journal:  J Diabetes Investig       Date:  2016-04-01       Impact factor: 4.232
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.